{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:21:06Z","timestamp":1792686066716,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>With the approval of the antibody-drug conjugate enfortumab vedotin (EV), NECTIN4 has emerged as a bona fide therapeutic target in urothelial carcinoma (UC). Here, we report the development of a NECTIN4-directed chimeric antigen receptor (CAR) T cell, which exhibits reactivity across cells expressing a range of endogenous NECTIN4, with enhanced activity in high expressors. We demonstrate that the PPAR\u03b3 pathway, critical for luminal differentiation, transcriptionally controls <jats:italic>NECTIN4<\/jats:italic>, and that the PPAR\u03b3 agonist rosiglitazone primes and augments NECTIN4 expression, thereby increasing sensitivity to NECTIN4-CAR T cell-mediated killing. NECTIN4-CAR T cells have potent anti-tumor activity even against EV resistant cells, which largely retain NECTIN4 expression, including in a post-EV biopsy cohort. Our results elucidate a therapeutically actionable mechanism that UC cells use to control NECTIN4 expression and suggest therapeutic approaches that leverage PPAR\u03b3 agonists for rational combinations with NECTIN4-targeting agents in UC, as well as future potential treatment options for EV-refractory patients.<\/jats:p>","DOI":"10.1038\/s41467-025-62710-0","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T09:03:59Z","timestamp":1757495039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Modulating the PPAR\u03b3 pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Kevin","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry M.","family":"Delavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corynn","family":"Kasap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1568-6629","authenticated-orcid":false,"given":"Roshan","family":"Lodha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-You","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2891-503X","authenticated-orcid":false,"given":"Alberto","family":"Carretero-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Basar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze","family":"Gokturk Ozcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2511-6731","authenticated-orcid":false,"given":"Min Yuen","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6614-802X","authenticated-orcid":false,"given":"David B.","family":"Solit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2938-6627","authenticated-orcid":false,"given":"Hikmat","family":"Al-Ahmadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9047-0222","authenticated-orcid":false,"given":"Cornelia C. K.","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Steri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima P.","family":"Porten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-8668","authenticated-orcid":false,"given":"Vadim S.","family":"Koshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence W.","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0963-7687","authenticated-orcid":false,"given":"Felix Y.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6570-2180","authenticated-orcid":false,"given":"John K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7465-6964","authenticated-orcid":false,"given":"Arun P.","family":"Wiita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carissa E.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1258-0391","authenticated-orcid":false,"given":"Jonathan","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"62710_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA: A Cancer J. Clin.74, 12\u201349 (2024).","journal-title":"CA: A Cancer J. Clin."},{"key":"62710_CR2","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","volume":"27","author":"CE Chu","year":"2021","unstructured":"Chu, C. E. et al. Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. Clin. Cancer Res. 27, 5123\u20135130 (2021).","journal-title":"Clin. Cancer Res."},{"key":"62710_CR3","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/cncr.34057","volume":"128","author":"VS Koshkin","year":"2022","unstructured":"Koshkin, V. S. et al. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer 128, 1194\u20131205 (2022).","journal-title":"Cancer"},{"key":"62710_CR4","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","volume":"37","author":"JE Rosenberg","year":"2019","unstructured":"Rosenberg, J. E. et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy. J. Clin. Oncol. 37, 2592\u20132600 (2019).","journal-title":"J. Clin. Oncol."},{"key":"62710_CR5","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","volume":"22","author":"EY Yu","year":"2021","unstructured":"Yu, E. Y. et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 22, 872\u2013882 (2021).","journal-title":"Lancet Oncol."},{"key":"62710_CR6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N. Engl. J. Med. 384, 1125\u20131135 (2021).","journal-title":"N. Engl. J. Med."},{"key":"62710_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719841581","volume":"10","author":"JC Chavez","year":"2019","unstructured":"Chavez, J. C., Bachmeier, C. & Kharfan-Dabaja, M. A. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Therapeutic Adv. Hematol. 10, 2040620719841581 (2019).","journal-title":"Therapeutic Adv. Hematol."},{"key":"62710_CR8","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain, M., Brentjens, R. & Rivi\u00e8re, I. The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388\u2013398 (2013).","journal-title":"Cancer Discov."},{"key":"62710_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong, M., Clubb, J. D. & Chen, Y. Y. Engineering CAR-T Cells for Next-Generation Cancer Therapy. Cancer Cell 38, 473\u2013488 (2020).","journal-title":"Cancer Cell"},{"key":"62710_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda, S. M. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. 21, 47\u201366 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"62710_CR11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.4049\/jimmunol.1402346","volume":"194","author":"K Watanabe","year":"2015","unstructured":"Watanabe, K. et al. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 \u03b6; chimeric antigen receptor-modified effector CD8+ T cells. J. Immunol. 194, 911\u2013920 (2015).","journal-title":"J. Immunol."},{"key":"62710_CR12","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219\u20131226 (2018).","journal-title":"Cancer Discov."},{"key":"62710_CR13","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner, R. G. et al. Tuning the antigen density requirement for CAR T cell activity. Cancer Discov. 10, 702\u2013723 (2020).","journal-title":"Cancer Discov."},{"key":"62710_CR14","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","volume":"25","author":"AJ Walker","year":"2017","unstructured":"Walker, A. J. et al. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. Mol. Ther. 25, 2189\u20132201 (2017).","journal-title":"Mol. Ther."},{"key":"62710_CR15","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.4049\/jimmunol.1700236","volume":"200","author":"DT Harris","year":"2018","unstructured":"Harris, D. T. et al. Comparison of T cell activities mediated by human TCRs and CARs that use the same recognition domains. J. Immunol. 200, 1088\u20131100 (2018).","journal-title":"J. Immunol."},{"key":"62710_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40265-019-01071-7","volume":"79","author":"M Mata","year":"2019","unstructured":"Mata, M. & Gottschalk, S. Engineering for success: approaches to improve chimeric antigen receptor T cell therapy for solid tumors. Drugs 79, 401\u2013415 (2019).","journal-title":"Drugs"},{"key":"62710_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1113882","volume":"14","author":"A Daei Sorkhabi","year":"2023","unstructured":"Daei Sorkhabi, A. et al. The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies. Front. Immunol. 14, 1113882 (2023).","journal-title":"Front. Immunol."},{"key":"62710_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","volume":"25","author":"G Guzman","year":"2023","unstructured":"Guzman, G., Reed, M. R., Bielamowicz, K., Koss, B. & Rodriguez, A. CAR-T therapies in solid tumors: opportunities and challenges. Curr. Oncol. Rep. 25, 479\u2013489 (2023).","journal-title":"Curr. Oncol. Rep."},{"key":"62710_CR19","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 16, 372\u2013385 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"62710_CR20","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-15-0139","volume":"75","author":"HG Caruso","year":"2015","unstructured":"Caruso, H. G. et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent anti-tumor activity. Cancer Res. 75, 3505\u20133518 (2015).","journal-title":"Cancer Res."},{"key":"62710_CR21","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.cell.2005.11.026","volume":"123","author":"M Lehrke","year":"2005","unstructured":"Lehrke, M. & Lazar, M. A. The many faces of PPARgamma. Cell 123, 993\u2013999 (2005).","journal-title":"Cell"},{"key":"62710_CR22","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","volume":"127","author":"X Wang","year":"2016","unstructured":"Wang, X. et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood 127, 2980\u20132990 (2016).","journal-title":"Blood"},{"key":"62710_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw2672","volume":"12","author":"D Wang","year":"2020","unstructured":"Wang, D. et al. Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. Sci. Transl. Med 12, eaaw2672 (2020).","journal-title":"Sci. Transl. Med"},{"key":"62710_CR24","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/mt.2014.208","volume":"23","author":"M Jonnalagadda","year":"2015","unstructured":"Jonnalagadda, M. et al. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol. Ther. 23, 757\u2013768 (2015).","journal-title":"Mol. Ther."},{"key":"62710_CR25","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/annonc\/mdw678","volume":"28","author":"M M-Rabet","year":"2017","unstructured":"M-Rabet, M. et al. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. Ann. Oncol. 28, 769\u2013776 (2017).","journal-title":"Ann. Oncol."},{"key":"62710_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420\u2013433 (2020).","journal-title":"Eur. Urol."},{"key":"62710_CR27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1046\/j.1464-5491.1999.00023.x","volume":"16","author":"C Day","year":"1999","unstructured":"Day, C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet. Med 16, 179\u2013192 (1999).","journal-title":"Diabet. Med"},{"key":"62710_CR28","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1124\/mol.106.033357","volume":"71","author":"S Hazra","year":"2007","unstructured":"Hazra, S. et al. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non\u2013small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol. Pharm. 71, 1715\u20131720 (2007).","journal-title":"Mol. Pharm."},{"key":"62710_CR29","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.euo.2021.11.005","volume":"5","author":"J Chou","year":"2022","unstructured":"Chou, J. et al. TROP2 expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant cells. Eur. Urol. Oncol. 5, 714\u2013718 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"62710_CR30","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3892\/ol.2023.14114","volume":"26","author":"M Abbas","year":"2023","unstructured":"Abbas, M. et al. Immunohistochemical expression of TROP\u20112 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer. Oncol. Lett. 26, 527 (2023).","journal-title":"Oncol. Lett."},{"key":"62710_CR31","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1073\/pnas.94.9.4318","volume":"94","author":"SA Kliewer","year":"1997","unstructured":"Kliewer, S. A. et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Natl Acad. Sci. 94, 4318\u20134323 (1997).","journal-title":"Proc. Natl Acad. Sci."},{"key":"62710_CR32","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/0092-8674(94)90006-X","volume":"79","author":"P Tontonoz","year":"1994","unstructured":"Tontonoz, P., Hu, E. & Spiegelman, B. M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79, 1147\u20131156 (1994).","journal-title":"Cell"},{"key":"62710_CR33","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1158\/0008-5472.CAN-17-1701","volume":"77","author":"JT Goldstein","year":"2017","unstructured":"Goldstein, J. T. et al. Genomic activation of PPARG reveals a candidate therapeutic axis in bladder cancer. Cancer Res. 77, 6987\u20136998 (2017).","journal-title":"Cancer Res."},{"key":"62710_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08157-y","volume":"10","author":"N Rochel","year":"2019","unstructured":"Rochel, N. et al. Recurrent activating mutations of PPAR\u03b3 associated with luminal bladder tumors. Nat. Commun. 10, 253 (2019).","journal-title":"Nat. Commun."},{"key":"62710_CR35","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7150\/jca.48976","volume":"12","author":"D Han","year":"2021","unstructured":"Han, D., Xu, Z., Zhuang, Y., Ye, Z. & Qian, Q. Current progress in CAR-T cell therapy for hematological malignancies. J. Cancer 12, 326\u2013334 (2021).","journal-title":"J. Cancer"},{"key":"62710_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/jha2.338","volume":"3","author":"S Sengsayadeth","year":"2021","unstructured":"Sengsayadeth, S., Savani, B. N., Oluwole, O. & Dholaria, B. Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice. EJHaem 3, 6\u201310 (2021).","journal-title":"EJHaem"},{"key":"62710_CR37","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-023-00373-7","volume":"12","author":"T Yan","year":"2023","unstructured":"Yan, T., Zhu, L. & Chen, J. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp. Hematol. Oncol. 12, 14 (2023).","journal-title":"Exp. Hematol. Oncol."},{"key":"62710_CR38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 21, 145\u2013161 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"62710_CR39","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41586-024-07018-7","volume":"626","author":"J Garcia","year":"2024","unstructured":"Garcia, J. et al. Naturally occurring T cell mutations enhance engineered T cell therapies. Nature 626, 626\u2013634 (2024).","journal-title":"Nature"},{"key":"62710_CR40","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1016\/j.cell.2023.08.013","volume":"186","author":"F Blaeschke","year":"2023","unstructured":"Blaeschke, F. et al. Modular pooled discovery of synthetic knockin sequences to program durable cell therapies. Cell 186, 4216\u20134234.e4233 (2023).","journal-title":"Cell"},{"key":"62710_CR41","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41586-022-05126-w","volume":"609","author":"J Carnevale","year":"2022","unstructured":"Carnevale, J. et al. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature 609, 174\u2013182 (2022).","journal-title":"Nature"},{"key":"62710_CR42","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ccell.2022.06.001","volume":"40","author":"JA Belk","year":"2022","unstructured":"Belk, J. A. et al. Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell 40, 768\u2013786.e767 (2022).","journal-title":"Cancer Cell"},{"key":"62710_CR43","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/JCI83416","volume":"126","author":"M Hegde","year":"2016","unstructured":"Hegde, M. et al. Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape. J. Clin. Invest. 126, 3036\u20133052 (2016).","journal-title":"J. Clin. Invest."},{"key":"62710_CR44","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.omto.2022.02.012","volume":"24","author":"N Muhammad","year":"2022","unstructured":"Muhammad, N. et al. A novel TanCAR targeting IL13R\u03b12 and EphA2 for enhanced glioblastoma therapy. Mol. Ther. Oncolytics 24, 729\u2013741 (2022).","journal-title":"Mol. Ther. Oncolytics"},{"key":"62710_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1032403","volume":"13","author":"R Mao","year":"2022","unstructured":"Mao, R., Kong, W. & He, Y. The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: moderate is better. Front Immunol. 13, 1032403 (2022).","journal-title":"Front Immunol."},{"key":"62710_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.958082","volume":"13","author":"F Li","year":"2022","unstructured":"Li, F. et al. Development of Nectin4\/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors. Front Immunol. 13, 958082 (2022).","journal-title":"Front Immunol."},{"key":"62710_CR47","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","volume":"29","author":"N Kl\u00fcmper","year":"2023","unstructured":"Kl\u00fcmper, N. et al. Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance. Clin. Cancer Res. 29, 1496\u20131505 (2023).","journal-title":"Clin. Cancer Res."},{"key":"62710_CR48","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/j.ccell.2023.11.004","volume":"41","author":"E Bergaggio","year":"2023","unstructured":"Bergaggio, E. et al. ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. Cancer Cell 41, 2100\u20132116.e2110 (2023).","journal-title":"Cancer Cell"},{"key":"62710_CR49","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934\u2013941 (2022).","journal-title":"Nature"},{"key":"62710_CR50","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1158\/2159-8290.CD-20-0242","volume":"11","author":"MA Nix","year":"2021","unstructured":"Nix, M. A. et al. Surface proteomics reveals CD72 as a target for in vitro\u2013evolved nanobody-based CAR-T cells in KMT2A\/MLL1-rearranged B-ALL. Cancer Discov. 11, 2032\u20132049 (2021).","journal-title":"Cancer Discov."},{"key":"62710_CR51","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nm.3159","volume":"19","author":"M Ahmadian","year":"2013","unstructured":"Ahmadian, M. et al. PPAR\u03b3 signaling and metabolism: the good, the bad and the future. Nat. Med. 19, 557\u2013566 (2013).","journal-title":"Nat. Med."},{"key":"62710_CR52","doi-asserted-by":"publisher","first-page":"e3001900","DOI":"10.1371\/journal.pbio.3001900","volume":"20","author":"Z Bahrami-Nejad","year":"2022","unstructured":"Bahrami-Nejad, Z. et al. Early enforcement of cell identity by a functional component of the terminally differentiated state. PLoS Biol. 20, e3001900 (2022).","journal-title":"PLoS Biol."},{"key":"62710_CR53","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc3214","volume":"12","author":"JM Peters","year":"2012","unstructured":"Peters, J. M., Shah, Y. M. & Gonzalez, F. J. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat. Rev. Cancer 12, 181\u2013195 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"62710_CR54","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.7150\/jca.42663","volume":"11","author":"T Peng","year":"2020","unstructured":"Peng, T. et al. The role and function of PPARgamma in bladder cancer. J. Cancer 11, 3965\u20133975 (2020).","journal-title":"J. Cancer"},{"key":"62710_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12332-0","volume":"10","author":"C Liu","year":"2019","unstructured":"Liu, C. et al. Pparg promotes differentiation and regulates mitochondrial gene expression in bladder epithelial cells. Nat. Commun. 10, 4589 (2019).","journal-title":"Nat. Commun."},{"key":"62710_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26421-6","volume":"12","author":"T Tate","year":"2021","unstructured":"Tate, T. et al. Pparg signaling controls bladder cancer subtype and immune exclusion. Nat. Commun. 12, 6160 (2021).","journal-title":"Nat. Commun."},{"key":"62710_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00147-w","volume":"8","author":"M Korpal","year":"2017","unstructured":"Korpal, M. et al. Evasion of immunosurveillance by genomic alterations of PPARgamma\/RXRalpha in bladder cancer. Nat. Commun. 8, 103 (2017).","journal-title":"Nat. Commun."},{"key":"62710_CR58","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy, J. A. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366, 1279\u20131289 (2005).","journal-title":"Lancet"},{"key":"62710_CR59","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/S0140-6736(11)61662-0","volume":"378","author":"D Hillaire-Buys","year":"2011","unstructured":"Hillaire-Buys, D., Faillie, J.-L. & Montastruc, J.-L. Pioglitazone and bladder cancer. Lancet 378, 1543\u20131544 (2011).","journal-title":"Lancet"},{"key":"62710_CR60","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/jama.2015.7996","volume":"314","author":"JD Lewis","year":"2015","unstructured":"Lewis, J. D. et al. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. JAMA 314, 265\u2013277 (2015).","journal-title":"JAMA"},{"key":"62710_CR61","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/cancers11030394","volume":"11","author":"DM Collins","year":"2019","unstructured":"Collins, D. M., Bossenmaier, B., Kollmorgen, G. & Niederfellner, G. Acquired resistance to antibody-drug conjugates. Cancers (Basel) 11, 394 (2019).","journal-title":"Cancers (Basel)"},{"key":"62710_CR62","doi-asserted-by":"publisher","unstructured":"Klumper, N. et al. NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer. J. Clin. Oncol. JCO2301983 https:\/\/doi.org\/10.1200\/JCO.23.01983 (2024).","DOI":"10.1200\/JCO.23.01983"},{"key":"62710_CR63","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.urolonc.2022.05.013","volume":"41","author":"C Chu","year":"2023","unstructured":"Chu, C. & Pietzak, E. Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non\u2013muscle invasive bladder cancer: Invited review for special issue \u201cSeminar: Treatment Advances and Molecular Biology Insights in Urothelial Carcinoma. Urologic Oncol.: Semin. Original Investig. 41, 398\u2013409 (2023).","journal-title":"Urologic Oncol.: Semin. Original Investig."},{"key":"62710_CR64","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.eururo.2021.10.009","volume":"81","author":"W Choi","year":"2022","unstructured":"Choi, W. et al. A Molecular inquiry into the role of antibody-drug conjugates in bacillus calmette-gu\u00e9rin-exposed non\u2013muscle-invasive bladder cancer. Eur. Urol. 81, 138\u2013142 (2022).","journal-title":"Eur. Urol."},{"key":"62710_CR65","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","volume":"26","author":"M Kates","year":"2020","unstructured":"Kates, M. et al. Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials. Clin. Cancer Res. 26, 882\u2013891 (2020).","journal-title":"Clin. Cancer Res."},{"key":"62710_CR66","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1158\/2326-6066.CIR-16-0267","volume":"5","author":"M Kates","year":"2017","unstructured":"Kates, M. et al. Intravesical BCG induces CD4+ T-cell expansion in an immune competent model of bladder cancer. Cancer Immunol. Res. 5, 594\u2013603 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"62710_CR67","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","volume":"150","author":"TL Ratliff","year":"1993","unstructured":"Ratliff, T. L., Ritchey, J. K., Yuan, J. J., Andriole, G. L. & Catalona, W. J. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J. Urol. 150, 1018\u20131023 (1993).","journal-title":"J. Urol."},{"key":"62710_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-20893-2","volume":"12","author":"A Rodriguez-Garcia","year":"2021","unstructured":"Rodriguez-Garcia, A. et al. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. Nat. Commun. 12, 877 (2021).","journal-title":"Nat. Commun."},{"key":"62710_CR69","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41568-022-00546-2","volume":"23","author":"ST Barry","year":"2023","unstructured":"Barry, S. T., Gabrilovich, D. I., Sansom, O. J., Campbell, A. D. & Morton, J. P. Therapeutic targeting of tumour myeloid cells. Nat. Rev. Cancer 23, 216\u2013237 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"62710_CR70","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N. Engl. J. Med. 390, 875\u2013888 (2024).","journal-title":"N. Engl. J. Med."},{"key":"62710_CR71","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","volume":"5","author":"SJ Bagley","year":"2024","unstructured":"Bagley, S. J. et al. Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial. Nat. Cancer 5, 517\u2013531 (2024).","journal-title":"Nat. Cancer"},{"key":"62710_CR72","doi-asserted-by":"publisher","unstructured":"Kim, B., Lee, C., Kim, Y. A. & Moon, K. C. PD-L1 Expression in muscle-invasive urinary bladder urothelial carcinoma according to basal\/squamous-like phenotype. Front. Oncol. 10, https:\/\/doi.org\/10.3389\/fonc.2020.527385 (2020).","DOI":"10.3389\/fonc.2020.527385"},{"key":"62710_CR73","first-page":"603.e609","volume":"38","author":"Y Yang","year":"2020","unstructured":"Yang, Y. et al. Programmed death-ligand 2 (PD-L2) expression in bladder cancer. Urologic Oncol.: Semin. Original Investig. 38, 603.e609\u2013603.e615 (2020).","journal-title":"Urologic Oncol.: Semin. Original Investig."},{"key":"62710_CR74","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","volume":"76","author":"PM Challita-Eid","year":"2016","unstructured":"Challita-Eid, P. M. et al. Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 76, 3003\u20133013 (2016).","journal-title":"Cancer Res."},{"key":"62710_CR75","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw5096","volume":"5","author":"I Minn","year":"2019","unstructured":"Minn, I. et al. Imaging CAR T cell therapy with PSMA-targeted positron emission tomography. Sci. Adv. 5, eaaw5096 (2019).","journal-title":"Sci. Adv."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62710-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62710-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62710-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:03:08Z","timestamp":1759402988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62710-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62710"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62710-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"assertion":[{"value":"2 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D. Solit has consulted\/received honoraria from Rain Pharmaceuticals, Pfizer, Fog Pharma, PaigeAI, BridgeBio, Scorpion Therapeutics, FORE Therapeutics, Function Oncology, Pyramid, Elsie Biotechnologies, Inc, and Meliora Therapeutics, Inc, all of which are outside the submitted work. H. Al Ahmadie has consulted for AstraZeneca and Paige.AI, all of which are outside the submitted work. J. Rosenberg served in a consulting or advisory role for Aktis, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Century Therapeutics, EMD Serono, Gilead, Century Therapeutics, Lilly Oncology, Pfizer, Roche\/Genentech, Merck, Samsung Bioepis, Tyra Bioscience, and Seattle Genetics; has received research support from Astellas, AstraZeneca, Seattle Genetics, Genentech\/Roche, Acrivon, and Lilly Oncology, all of which are outside the submitted work. C.K. Ding has consulted for Intuitive and reports research funding from Bristrol Myers Squibb, all of which are outside the submitted work. S.P. Porten reports research funding from Photocure and Kdx, honoraria from Fergene and CG Oncology, and serves on the steering committee or advisory board for Janssen and Vesica Health, all of which are outside the submitted work, all of which are outside the submitted work. T.W. Friedlander reports research funding from Seagen\/Pfizer and Roche\/Genetech, and has served in a consulting role for Astellas, Merck, Seagen\/Pfizer, Gilead, Bicycle Therapeutics, Atkis Oncology, Bristol Meyers Squibb, and Abbvie, all of which are outside the submitted work. V.S. Koshkin has served in a consulting or advisory role for Astellas, Bicycle Therapeutics, Janssen, EMD Serono, Loxo Oncology, MSD, Seagen\/Pfizer; has received institutional research funding from Endocyte\/Novartis, Curium, Nektar, Gilead, Taiho, Merck and Seagen\/Pfizer; and individual research funding from Eli Lilly, all of which are outside the submitted work. F.Y. Feng reported personal fees from Bluestar Genomics, Astellas, Foundation Medicine, Exact Sciences, Tempus, POINT Biopharma, Janssen, Bayer, Myovant, Roivant, SerImmune, Bristol Meyers Squibb, Novartis, and personal fees from POINT Biopharma and other support from Artera, prior to his death, all of which are outside the submitted work. J.K. Lee holds equity in, is on the scientific advisory board of, and receives research funding from PromiCell Therapeutics, outside the submitted work. He is an inventor on International Patent Application No. PCT\/US2023\/074229 related to NECTIN4 chimeric antigen receptor T cell therapy. A.P. Wiita reports being an equity holder in Indapta Therapeutics and speaker honoraria from Sanofi and AstraZeneca, all of which are outside the submitted work. J. Chou reports consulting fees from Exai Bio and Bicycle Therapeutics outside the submitted work. K. Chang and J. Chou have filed a provisional patent through the University of California Office of Technology and Management based on this work. All other authors report no disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8215"}}